CS-003 free base (CS-003) is a triple tachykinin receptor antagonist with high affinity for human (neurokinin) NK1, NK2 and NK3 receptors, with Ki values of 2.3 nM and 0.54 nM, respectively And 0.74 nM. CS-003 free base (CS-003) has therapeutic effects on
CGP 45715A (irukostat) is a potent peptide-leukotriene antagonist used to treat respiratorydiseases by antagonizing the bronchial constriction, mucus secretion, and inflammatory effects of these leukotrienes.
Substance P Receptor Antagonist 1 has the potential function in gastrointestinal disorders, inflammatory diseases, respiratory, and central nervous system disorders.
Dexbrompheniramine is an antihistamine with anticholinergic properties. It is used to treat allergic diseases such as hay fever or urticaria. It can compete with histamine for H1 receptor sites on effector cells of the gastrointestinal tract, blood vessel
GSK3527497 is a potent and selective inhibitor of Transient Receptor Potential Vanilloid‑4 (TRPV4) with IC50 = 12 nM) for the treatment of heart failure and respiratorydiseases. GSK3527497 is a preclinical candidate suitable for oral and iv administration that is projected to inhibit TRPV4 effectively in patients from a low daily clinical dose.
BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases, respiratorydiseases, inflammation, and diabetes.
Memotine HCl has antiviral activity against respiratory tract infection and is used as a therapeutic agent for acute respiratorydiseases. It is also a memo fracture in the form of hydrochloride, an isoquinoline, with anti-myxovirus and paramyxovirus acti
EICAR is a drug which acts as an inhibitor of the enzyme IMP dehydrogenase. It is a nucleoside derivative which has both anti-cancer and antiviral effects, and was originally developed for the treatment of leukemia, but was unsuccessful in human clinical trials. It has broad spectrum antiviral effects with activity against vaccinia virus, Semliki forest virus, Junin virus, reovirus, influenza, measles virus and respiratory syncytial virus among others, although it is not active against SARS. This useful spectrum of activity means that EICAR and related derivatives continue to be investigated for the treatment of viral diseases.